Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Nicholson, Luke
Vazquez-Alfageme, Clara
Sivagnanavel, Vasuki
Fausto, Riccardo
Soare, Maria Cristina
Salamanca, Marta Bautista
Fabozzi, Lorenzo https://orcid.org/0000-0002-2449-9542
Tsika, Chrysanthi
Corbalan, Olga Cejudo
Verdejo, Alejandro Gomez
Wakabayashi, Taku https://orcid.org/0000-0003-2640-6079
Woo, Se Joon https://orcid.org/0000-0003-3692-7169
Kolomeyer, Anton M.
Mansour, Hana
Momenaei, Bita
Regillo, Carl D.
,
Kuppermann, Baruch D.
Loewenstein, Anat
Bandello, Francesco
Querques, Giuseppe
Ueda-Consolvo, Tomoko
Ishida, Masaaki
Nakamura, Tomoko
Yanagisawa, Shuichiro
Hayashi, Atsushi
Tsuboi, Kotaro
Kumar, Nilesh
Parachuri, Nikulaa
Sheth, Jay
Ayachit, Seemantini
Mishra, Chitaranjan
Chakraborty, Debdulal
Banker, Alay
Rezaei, Kourous A.
Khanani, Arshad M.
Kaiser, Peter K.
Holz, Frank G.
Sivaprasad, Sobha
Özdek, Şengül
Laurent, Kodjikian
Bilgic, Alper
Lanzetta, Paolo
Sarao, Valentina
Baumal, Caroline
Holekemp, Nancy
Sakamoto, Taiji
Tufail, Adnan
Yannuzzi, Nicolas
Sridhar, Jayanth
Corradetti, Giulia
Hilely, Assaf
Boyer, David
Rachitskaya, Aleksandra
Peto, Tunde
Wintergerst, Maximilian W. M.
Parolini, Barbara
Mruthyunjaya, Prithvi
Nguyen, Quan Dong
DO, Diana V.
Keane, Pearse A.
Hassan, Tarek
Eichenbaum, David
Grewal, Dilraj S.
March, Francesc
Spitzer, Martin S.
Falavarjani, Khalil G.
Zinkernagel, Martin S.
Lee, Christopher Seungkyu
Kim, Judy E.
- License Information
-
More Information
Article History
Received: 17 March 2025
Revised: 2 September 2025
Accepted: 16 September 2025
First Online: 2 October 2025
Competing interests
: Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Luke Nicholson- None. Clara Vazquez-Alfageme- None. Vasuki Sivagnanavel – None. Riccardo Fausto – None. Maria Cristina Soare – None. Marta Bautista Salamanca – None. Lorenzo Fabozzi- None. Chrysanthi Tsika- None. Olga Cejudo Corbalan – None. Alejandro Gomez Verdejo-None. Hana Mansour- None. Bita Momenaei – None. Taku Wakabayashi- None. Se Joon Woo- Dr Woo reported serving as a consultant for Samsung Bioepis and Panolos Bioscience; being cofounder of Retimark; serving as an advisory board member of Novartis and Novelty Nobility; receiving grants and personal fees from Samsung Bioepis, Novartis, Novelty Nobility, Alteogen, Kookje, and Curacle; and receiving lecture fees from Novartis, Bayer, Allergan, AbbVie, Alcon, Taejoon, SCAI Therapeutics, and Alteogen. Anton M Kolomeyer- -None. Carl D Regillo: Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Bausch and Lomb, Clearside, Cognition, EyePoint, Genentech, Iveric, Janssen, Kodiak, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Ocuphire, Opthea, Ray, RegenXBio, Stealth, Thea, Zeiss; Research grant support: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, Iveric, Janssen, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.
: In this preliminary study conducted in clinical settings, the ranibizimab biosimilar (FYB 201) demonstrated efficacy across a range of vascular endothelial growth factor (VEGF)-driven macular disorders. The safety profile of the ranibizumab biosimilar (FYB 201) was observed to be comparable to that of the reference product (Lucentis, Genentech, USA).
